P1.10-02 ImmunoPET: A Phase 0/1 Study Characterising PD-L1 with 89Zr-Durvalumab (MEDI4736) PET/CT in Stage III NSCLC Patients Receiving Chemoradiation

ImmunoPET is a multicentre, single arm, phase 0-1 study investigating the use of 89Zr-durvalumab PET/CT to interrogate the expression of PD-L1 in patients with NSCLC, in preparation for large clinical trials. We describe novel processes for automated production of zirconium-labelled Immune-PET tracers, validation processes and imaging credentialing for a multicentre trial of 89Zr-durvalumab (89Zr-durva) to characterize PD-L1 upregulation during the treatment of locally advanced non-small cell lung cancer (NSCLC) patients receiving radical chemoradiotherapy.